This drug holds promise for arthritis treatment: Researchers

London: Researchers have identified a drug that can significantly reduce bone and cartilage progression in osteoarthritis.

In a study, the researchers found that “MIV-711” — a novel selective cathepsin K inhibitor — can reduce disease progression in osteoarthritis. However, the drug was not more effective than placebo for reducing pain related to knee osteoarthritis.

Osteoarthritis of the knee is a painful, disabling condition affecting more than 14 million people in the US and hundreds of millions worldwide.

The pain of knee osteoarthritis arises from a series of pathologic processes involving articular cartilage, subchondral bone, synovium, meniscus, and other joint structures, ultimately leading to joint failure and pain-related functional limitations.

A team of researchers led by the University of Leeds in the UK, sought to test the hypothesis that cathepsin K inhibitor could alleviate osteoarthritis symptoms by reducing the degeneration of bone and cartilage. (IANS)

Also Read: Premature Births Another Cause of Arthritis

Also watch: Forest Minister Parimal Suklabaidya honours elephant calf with ‘Assamese Gamosha’ on Jan 1, 2020